The role of T cells in the treatment of Parkinson’s disease
PeerJ · 2025
DOI: 10.7717/peerj.19818 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PeerJ, 2025. Verfasst von Zhuomiao Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Meizhou People's Hospital (Huangtang Hospital), Meizhou, Guangdong, China. Hauptthemen laut MEDLINE: Parkinson Disease, T-Lymphocytes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Nature Science Foundation of China, GuangDong Basic and Applied Basic Research Foundation, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Current pharmacological treatment of Parkinson’s disease (PD) predominantly employs dopaminergic agents aimed at enhancing cerebral dopamine levels. While these therapeutic strategies provide symptomatic relief, their palliative nature is frequently associated with dose-dependent complications, including gastrointestinal disturbances, emetic symptoms, and motor complications such as dyskinesia. Moreover, the honeymoon period of drugs has greatly limited their clinical application. The multifactorial etiology of PD continues to challenge researchers, yet substantial evidence implicates α-synuclein as a critical pathogenic mediator. Emerging findings suggest that dysregulated neuroimmune interactions constitute a fundamental mechanism in PD progression, where chronic immune activation appears particularly detrimental to neuronal survival. Notably, neuroinflammatory cascades coupled with compromised blood-brain barrier (BBB) integrity create a self-perpetuating cycle of neural degeneration, wherein α-synuclein-specific T cells exacerbate disease pathology while regulatory T cell populations demonstrate potential immunomodulatory capacities. This review systematically examines the mechanistic interplay involving neuroinflammatory cascades, BBB compromise, central nervous system (CNS) immunoregulation, and T lymphocyte subpopulations (including regulatory T cells) in the pathogenesis of PD. By synthesizing current evidence, we aim to establish a conceptual framework supporting the investigation of cellular immunity-based therapies for PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Meizhou People's Hospital (Huangtang Hospital), Meizhou, Guangdong, China.
- Department of Pharmacy, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China.
- Department of Orthopaedics and Traumatology, The Seventh Affiliated Hospital, Southern Medical University, Foshan, Guangdong, China.
Förderung
- National Nature Science Foundation of China
- GuangDong Basic and Applied Basic Research Foundation
- China Postdoctoral Science Foundation
- Scientific Research Starting Foundation for High-level Talents of Meizhou People’s Hospital
- Shining Across China-Medicinal Research Fund
- Social Development Science and Technology Plan Project of Meizhou
Zitieren
APA
Lin, Z., Yu, X., Zhong, Y., Tan, G., & Zhong, J. (2025). The role of T cells in the treatment of Parkinson’s disease. PeerJ. https://doi.org/10.7717/peerj.19818
Vancouver
Lin Z, Yu X, Zhong Y, Tan G, Zhong J. The role of T cells in the treatment of Parkinson’s disease. PeerJ. 2025. doi:10.7717/peerj.19818
BibTeX
@article{Lin2025,
author = {Lin, Zhuomiao and Yu, Xihui and Zhong, Yunming and Tan, Guozhu and Zhong, Jiahong},
title = {The role of T cells in the treatment of Parkinson’s disease},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.19818}
}
EUVIMED